Abstract |
We explored market factors that affect pediatric combination vaccine uptake in the US public-sector pediatric vaccine market. We specifically examined how Pediarix and Pentacel earned a place in the 2009-2012 lowest overall cost formulary. Direct competition between Pediarix and Pentacel is driven by the indirect presence of the Merck Haemophilus influenzae type b vaccine and the Recommended Childhood Immunization Schedule requirement for a hepatitis B birth dose. The resulting analysis suggests that Pentacel would never have earned a place in the lowest overall cost formulary for 2009-2012 federal contract prices for any cost of an injection unless the Merck H influenzae type b advantage was ignored and the hepatitis B birth dose administration cost was recognized by health care providers in designing the lowest overall cost formularies.
|
Authors | Banafsheh Behzad, Sheldon H Jacobson, Janet A Jokela, Edward C Sewell |
Journal | American journal of public health
(Am J Public Health)
Vol. 104
Issue 6
Pg. 998-1004
(Jun 2014)
ISSN: 1541-0048 [Electronic] United States |
PMID | 24825198
(Publication Type: Journal Article, Research Support, U.S. Gov't, Non-P.H.S.)
|
Chemical References |
- Diphtheria-Tetanus-Pertussis Vaccine
- Haemophilus Vaccines
- Hepatitis B Vaccines
- PEDIARIX
- Poliovirus Vaccine, Inactivated
- Vaccines, Combined
- pentacel
|
Topics |
- Child
- Child, Preschool
- Diphtheria-Tetanus-Pertussis Vaccine
(economics, therapeutic use)
- Drug Costs
- Drug Industry
(economics)
- Haemophilus Vaccines
(economics, therapeutic use)
- Hepatitis B Vaccines
(economics, therapeutic use)
- Humans
- Immunization Programs
(economics)
- Infant
- Infant, Newborn
- Poliovirus Vaccine, Inactivated
(economics, therapeutic use)
- United States
- Vaccines, Combined
(economics, therapeutic use)
|